DVSMCs were treated with IL-17, IL-9, IL-17, and IL-9, IL-17 neutralizing antibody and IL-9 neutralizing antibody, IL-17 and IL-9 and tanshinone IIA, SSc serum, SSc serum/IL-17 neutralizing antibody/IL-9 neutralizing antibody, and SSc serum and tanshinone IIA for 3 days. The gene discussed is IL17A; the disease is systemic sclerosis.